p53 and Ki-67 overexpression in gastroesophageal reflux disease - Barrett's esophagus and adenocarcinoma sequence

Diseases of the Esophagus

Volumn 22, Issue 7, 2009, Pages 588-595

  Binato, M ^a,b,d   Gurski, R R ^a,b,c   Fagundes, R B ^a,b,c,d   Meurer, L ^a,c   Edelweiss, M I ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d Academic Hospital of Santa Maria HUSM   (Brazil)

Author keywords

Adenocarcinoma; Barrett's esophagus; Gastroesophageal reflux disease; Ki 67 (MIB 1); p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADENOCARCINOMA; ADULT; ARTICLE; BARRETT ESOPHAGUS; DISEASE COURSE; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS TUMOR; GASTROINTESTINAL ENDOSCOPY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MUCOSA; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; ESOPHAGUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73949099910     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00953.x     Document Type: Article

References (57)

1. Voutilainen M, Sipponen P, Mecklin J P, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6-13.
2. Avidan B, Sonnenberg A, Schnell TG, Sontag S J. There are no reliable symptoms for erosive esophagitis and Barrett's esophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002; 16 (4): 735-42.
3. Moraes-Filho J P P, Cecconello I, Gama-Rodrigues J et al. Brazilian Consensus Group. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol 2002; 97: 241-8.
4. Achem S R. Endoscopy negative gastroesophageal reflux disease. The hypersensitive esophagus. Gastroenterol Clin North Am 1999; 28: 893-904.
5. Younes M, Ertan A, Lechago L V, Somoano J R, Lechago J. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. DigDis Sci 1997; 42: 697-701.
6. Gillen P, Keeling P, Byrne P J, West AB, Hennessy T P. Experimental columnar metaplasia in the canine esophagus. Br J Surg 1988; 75: 113-5.
7. Bremner C G, Lynch V P, Ellis H F. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68: 209-16.
8. Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterol. Am J Gastroenterol 1998; 93 (7): 1028-32.
9. Cameron A J, Zinsmeister A R, Ballard D J, Carney J A. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterol 1990; 99 (4): 918-22.
10. Lieberman D A, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293-7.
11. Devesa S, Blot W F, Fraumeni J F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83 (10): 2049-53.
12. Sharma P, Morales T G, Samplimer R E. Short segment Barrett's esophagus: the need for standardization of the definition and endoscopic criteria. Am J Gastroenterol 1998; 93 (7): 1033-6.
13. DeMeester S R, DeMeester T R. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000; 231 (3): 303-21.
14. Hameeteman W, Tytgat G N, Houthoff H J, van den Tweel J G. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterol 1989; 96 (5): 1249-56.
15. Wijnhoven B P, Tilanus HW, DinjensWN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001; 233 (3): 322-37.
16. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130 (11): 883-90.
17. Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar- lined (Barrett's) esophagus. N Engl JMed 1985; 313: 857-9.
18. Kim R, Clarke M R, Melhem M F et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997; 42: 2453-62.
19. Krishnadath K K, Tilanus HW, BlankeisteinMV et al. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's esophageal. J Pathol 1995; 75: 175-80.
20. Neshat K, Sanchez C A, Galipean P C et al. p53 mutation in Barrett's adenocarcinoma and high grade dysplasia. Gastroenterol 1994; 106: 1589-95.
21. Nigro J M, Baker S J, Preiseinger A C et al. Mutations in the p53 gene occur in diverse human types. Nature 1989; 342: 705-8.
22. Bennett W P, Hollstein M C, He A et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991; 6: 1779-84.
23. Oberg S, Peters J H, DeMeester T R et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997; 226 (4): 522-30.
24. Kauer W K, Peters J H, DeMeester T R et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995; 222 (4): 525-31.
25. Lopes C V, Pereira-Lima J, Hartmann Aa et al. O critério de positividade para a análise imunoistoquímica da p53 na confirmação da displasia do esôfago de Barrett faz diferença?. Ar Gastroenterol 2005; 42 (4): 233-8.
26. Younes M, Lebovitz R L M, Lechago L V et al. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. Gastroenterol 1993; 105: 1637-142.
27. Hong M K, Laskin W B, Herman B E et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995; 75: 423-9.
28. Herbst J J, Berenson M M, Mccloskey D W et al. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterol 1978; 75: 683-7.
29. Gerdes J, BeckerMH, Key G et al. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalinfixed and routinely processed tissues. J Pathol 1992; 168 (1): 85-6.
30. Gerdes J, Lemke H, Braisch H et al. Cell cycle of a proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-15.
31. Polkowski W, van Lanschot J J, ten Kate F J et al. The value of p53 and Ki-67 as markers for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995; 4: 163-71.
32. Reid B J, Sanchez C A, Blount P L et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterol 1993; 105 (1): 119-29.
33. Nishiyama Y, Koyama S, Andoh A et al. Immunohistochemical analysis of cell cycle-regulating-protein (p21, p27, and Ki-67) expression in gastroesophageal reflux disease. J Gastroenterol 2002; 37 (11): 905-11.
34. Porschen R, Kriegel A, Langen C et al. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer 1991; 47 (5): 686-91.
35. Chen X, Ouyang Q, ZhangWY et al. The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett's esophagus. Sichuan Da Xue Xue Bao Yi Xue Ban 2005; 36 (2): 207-9.
36. Iftikhar S Y, Steele R J, Watson S et al. Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's esophagus. Gut 1992; 33 (6): 733-7.
37. Jankowski J, Coghill G, Hopwood D et al. Oncogenes and oncosupressor genes in adenocarcinoma of the esophagus. Gut 1991; 32: A1205-6.
38. Reid B J, Haggitt R C, Rubin C E et al. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterol 1987; 93 (1): 1-11.
39. Yoshikawa I, Yamasaki M, Kume K, Tabaru A, Otsuki M. Lugol chromoendoscopy as a diagnostic tool in so-called endoscopy-negative GERD. Gastrointest Endosc 2005; 62 (5): 698-703.
40. Brown D C, Gatter K C. Monoclonal antibody Ki-67: its use in histopathology. Histopathol 1990; 17 (6): 489-503.
41. Levine D S, Haggitt R C, Irvine S. Natural history of highgrade dysplasia in Barrett's esophagus. Gastroenterol 1993; 105: 40-50.
42. Flora-Filho R, Câmara-Lopes L H, Zilberstein B. Critérios histológicos na doença do refluxo gastroesofágico. Reavaliação da sensibilidade da pHmetria esofágica de 24 horas. Arq Gastroenterol 2000; 37 (4): 1-10.
43. Siewert J R, Holscher A H, Becker K, Gossner W. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg 1987; 58 (1): 25-32. (In German.)
44. Weston A P, Banerjee S K, Sharma P et al. R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96 (5): 1355-62.
45. Wang L D, Hong J Y, Qiu S L et al. Accumulation of P53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 1993; 53: 1783-7.
46. Feith M, Stein H J, Mueller J et al. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 2004; 17 (4): 322-7.
47. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340 (11): 825-31.
48. Ramel S, Reid B J, Sanches C A et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterol 1992; 102: 1220-8.
49. Polkowski W, Van Lanschot J J B, Offerhaus G J A. Barrett esophagus and cancer: pathogenesis, carcinogenesis, and diagnostic dilemmas. Histopathol 1999; 14: 927-44.
50. Clark GW, Ireland A P, DeMeester T R. Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment. Dig Dis 1996; 14 (4): 213-27.
51. Mandard A M, Marnay J, Lebeau C et al. Expression p53 in esophageal squamous epithelium from surgical specimens resected for carcinoma of the esophagus, with special reference to uninvolved mucosa. J Pathol 1997; 181 (2): 153-7.
52. Cattoretti G, Becker M H, Key G, Duchrow M et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferation cells in microwave-processed formal in fixed paraffin section. J Pathol 1992; 168: 357-63.
53. Adulaimi D, Jankowski J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus 1999; 12 (3): 177-80.
54. Segal F, Kaspary A P, Prolla J C, Leistner S. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Lett 2002; 210 (2): 213-8.
55. Fagundes R B, Melo C R, Putten A C, Moreira L F, Barros S G. p53 immunoexpression: an aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk?. Cancer Detect Prev 2005; 29 (3): 227-32.
56. Casson A G, Mukhopaday T, Cleary K R et al. P53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991; 51: 4495-9.
57. Rice T W, Goldblum J R, Falk G W, Tubs R R, Kirby T J, Casey G. p53 Immunoreactive in Barrett's metaplasia, dysplasia, and carcinoma. J Thoracic Cardiovasc Surg 1996; 111: 323-31.